Haemochromatosis International and the European Federation of Associations of Patients with Haemochromatosis are guided by a joint scientific advisory committee made up of eminent researchers and clinicians from around the world.
There is a long track record of good interaction and collaboration between the scientific community and haemochromatosis patients’ associations, reflected not only in the regular participation of experts in their annual meetings and conferences, and in the participation of patients at the BioIron and European Iron Club Meetings, but also in the execution and promotion of patient oriented projects such as the publication and translation of the Therapeutic Guidelines, and the ongoing HARI project, on the study of hemochromatosis arthropathy.
There are also good interactions in science oriented projects where patients have been invited to participate, such as in the publication of the EMQN best practice guidelines for the molecular diagnosis of HH (Eur J Hum Genet, 2016;24:479-95), the EASL clinical practice guidelines for HFE hemochromatosis ( J Hepatol. 2022 77(2):479-502) as well as the recent update and recommendations of Hemochromatosis nomenclature and classification ( Blood. 2022 ;139(20):3018-3029).
The Chair of the Joint Scientific Committee is Professor Graça Porto. Current members are listed in the table below.
|Dr||Butzeck||Barbara||Germany||Patients’ representative (HARI project)|
|Dr||de Graaff||Barbara||Australia||Health Economics|
|Mr||Don||Howard||UK||Patients’ representative (President HI)|
|Prof||Santos||Paulo||Brazil||Clinical & molecular pathology|
|Prof||Swinkels||Dorine||Netherlands||Clinical & molecular pathology|
|Mr||Toska||Ketil||Norway||Patients’ representative (President EFAPH)|